High uptake of PSA testing linked to lower mortality

The researchers compared prostate outcomes in eight Swedish counties with early uptake of PSA screening against outcomes in six counties slow to adopt the test. The study covered more than 2500 prostate cancer deaths.

The authors found incidence of metastatic prostate cancer was 15% lower and prostate cancer-specific mortality was 19% lower in areas of high versus low incidence of cancer, reflecting uptake of PSA. Excess mortality was also 26% lower with more intense testing.

J Nat Cancer Instit 2014; online 7 March